Seeking Alpha

Neuralstem (CUR) jumps 12.1% after it receives approval from the FDA to start a Phase I safety...

Neuralstem (CUR) jumps 12.1% after it receives approval from the FDA to start a Phase I safety trial of its lead cell therapy treatment, NSI-566, in eight patients who have become complete paralyzed due to spinal-cord injuries. Neuralstem has already conducted 18 successful surgeries using the same cells and surgical device that it will use in the new trial. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector